| Name | Title | Contact Details |
|---|
Cholestech Corporation (Cholestech) is a provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes. The Company manufactures and markets the LDX System in the United States and
Hayden Medical Inc is a Santa Clarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gyrus Medical Inc. is a Osseo, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. As The Imaging Phenomics Company®, Median provides insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for lesion management in patient care, Lesion Management Solution (LMS) for lesion detection, measurement and reporting in clinical trials, and our imaging phenotyping system iBiopsy®, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world in bringing new and targeted treatments to patients in need with an eye on reducing overall costs. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris` Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017.
ARTIO MEDICAL, formerly known as Metactive Medical, is developing innovative endovascular medical devices with the potential to provide immediate and lasting occlusion of aneurysms, blood vessels, and other vascular structures. Artio`s products enable precision placement and provide immediate, complete, and lasting occlusion of target vessel segments and saccular aneurysms. These products will enable physicians to perform better, faster, and safer vascular occlusion procedures.